Compare Novavax Inc (NVAX) vs IAC/Interactivecorp (PPLI) Price & Performance

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.

PPLI trades at $38.38, down 1.56% today, with a bearish technical signal from moving averages. The company reported mixed quarterly results, including a significant Q2 2026 earnings beat of $6.77 per share versus expectations of a $0.40 loss, driven by gains from its MGM investment. Revenue has declined from $5.2B in 2022 to $2.4B in 2025, though 2026 projections show improved profitability with a 14.12% net margin. Recent news highlights participation in investor conferences and strategic focus on monetizing non-core assets.

The investment outlook is cautiously optimistic, supported by a 69% analyst buy rating and a $58.80 consensus price target implying 53% upside. Key opportunities include the undervalued MGM stake exceeding market cap and improving digital revenue. Risks involve declining revenue trends, negative operating cash flow in 2026, and a shareholder investigation announced in August 2026. The stock's low P/E of 6.49 and P/B of 0.56 suggest valuation appeal if execution improves.